1Mentlein R. Dipeptidyl-peptidase Ⅳ (CD 26)-role in the inactivation of regulatory peptides[J]. Regul Pept, 1999,85 ( 1 ) : 9-24. 被引量：1
2Gefel D, Hendrick GK, Mojsov S, et al. Glucagon-like peptide-Ⅰ analogs: effects on insulin secretion and adenosine 3', 5' monophosphate formation[J].Endocrinology, 1990,126(4) : 2164-2168. 被引量：1
3Flock G, Baggio LL, Longuet C, et al. Incretin receptors for glucagon like peptide 1 and glucose-dependent insulinotropie polypeptide are essential for the sustained metabolic actions of vildagliptin in mice[J]. Diabetes,2007,56(12) :3006-3013. 被引量：1
4Lamont BJ, Drucker DJ. Differential antidiabetic efficacy of incretin agonists versus DPP 4 inhibition in high fat fed mice[J]. Diabetes, 2008,57(1) :190-198. 被引量：1
5Moritoh Y,Takeuchi K,Asakawa T,et al. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase 4 inhibitor,improves glycemic control and β-cell function in obese diabetic ob/ob mice[J]. Eur J Pharmacol,2008,588(2-3) :325-332. 被引量：1
6Ahren B, Sorhede Winzell M, Burkey B, et al. β-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice[J]. Eur J Pharmacol,2005,521(1 3) :164-168. 被引量：1
7Ahren B, Hughes TE. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glueagon- like peptide-1, glucose-dependent insulinotropie polypeptide, pituitary adenylate cyclase activating polypeptide, and gastrin-releasing peptide in mice[J]. Endocrinology, 2005,146 (4) : 2055-2059. 被引量：1
8Azuma K,Radikova Z,Mancino J ,et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes[J]. J Clin Endocrinol Metab,2008,93(2):459-464. 被引量：1
9Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes[J]. Diabetes Obes Metab, 2008,18[Epub ehead of prints]. 被引量：1
10Pratley RE, Jauffret-Kamel S, Galbreath E, et al. Twelve Week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes[J]. Horm Metah Res, 2006,38(6) : 423-428. 被引量：1
二级参考文献25
1LUDWIG A,SCHIEMANN F,MENTLEIN R,et al.Dipeptidyl peptidase Ⅳ (CD26) on T cells cleaves the CXC chemokine CXCL11 (I-TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine[J].J Leukoc Biol,2002,72(1):183-191. 被引量：1
2BROXMEYER H E,KOHLI L,KIM C H.Stromal cell-derived factor-1/CXCL12 directly enhances survival/antiapoptosis of myeloid progenitor cells through CXCR4 and G(a) i proteins and enhances engraftment of competitive,repopulating stem cells[J].J Leukoc Biol,2003,73 (5):630-638. 被引量：1
3JONES B,ADAMS S,MILLER G T,et al.Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies[J].Blood,2003,102(5):1641-1648. 被引量：1
4ENGEL M,HOFFMANN T,WAGNER L,et al.The crystal structure of dipeptidyl peptidase Ⅳ (CD26) reveals its functional regulation and enzymatic mechanism[J].Proc Natl Acad Sci SA,2003,100(9):5063-5068. 被引量：1
5MARI A,SALLAS W M,HE Y L,et al.Vildagliptin,a dipeptidyl peptidase-Ⅳ inhibitor,improves model-assessed beta-cell function in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2005,90 (8):4888-4894. 被引量：1
6HERMAN G A,STEVENS C,VAN DYCK K,et al.Pharmacokinetics and pharmacodynamics of sitagliptin,an inhibitor of dipeptidyl peptidase Ⅳ,in healthy subjects:results from two randomized,double-blind,placebo-controlled studies with single oral doses[J].Clin Pharmacol Ther,2005,78 (6):675-688. 被引量：1
7RAZI I,HANEFELD M,XU L.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus[J].Diabetologia,2006,49 (11):2564-2571. 被引量：1
8AHREN B,GOMIS R,STANDL E,et al.Twelve-and 52-week efficacy of the dipeptidyl peptidase Ⅳ LAF237 in metformin-treated patients with type 2 diabetes[J].Diabetes Care,2004,27(12):2874-2880. 被引量：1
9SCOTT R,HERMAN G,ZHAO P,et al.Twelve-week efficacy and tolerability of MK-0431,a dipeptidyl peptidase Ⅳ (DPPⅣ) inhibitor,in the treatment of type 2 diabetes[J].Diabetologia,2005,48(Suppl 1):287. 被引量：1
10CHYAN Y J,CHUANG L M.Dipeptidyl peptidase-Ⅳ inhibitors:an evolving treatment for type 2 diabetes from the incretin concept.recent patents on endocrine[J].Metabolic & Immune Drug Discovery,2007,1 (10):15-24. 被引量：1
1Matsuyama-Yokono A, Tahara A, Nakano R, et al. Antidiabetic effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice[J]. Metabolism, 2009, 58(3): 379-386. 被引量：1
2Deacon CF, Hoist JJ. Dipeptidyl peptidase-4inhibitors: a promising new therapeutic approach for the management of type 2 diabetes[J]. Int J Biochem Cell Biol, 2006, 38(526): 831-844. 被引量：1
3Azuma K, Radikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2008, 93( 2): 459-464. 被引量：1
4Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes[J]. Diabetes Obes Metab, 2008, 10(5): 376-386. 被引量：1
5Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, et al. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2008, 10( 4): 293-300. 被引量：1
6Deacon CF. Circulation and degradation of GIP and GLP-1 [J]. Horm Metab Res, 2004, 36 (11-12): 761-765. 被引量：1
7Mentlein R. Dipeptidyl-peptidase 4(CD26)-role in the inactivation of regulatory peptides[J]. Regul Pept, 1999, 85(1): 9-24. 被引量：1
